| 000 | 01001 a2200265 4500 | ||
|---|---|---|---|
| 005 | 20250514015811.0 | ||
| 264 | 0 | _c20020517 | |
| 008 | 200205s 0 0 eng d | ||
| 022 | _a0277-0008 | ||
| 024 | 7 |
_a10.1592/phco.21.11.1015.34515 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKalus, J S | |
| 245 | 0 | 0 |
_aEnoxaparin should be used cautiously in patients with end-stage renal disease. _h[electronic resource] |
| 260 |
_bPharmacotherapy _cAug 2001 |
||
| 300 |
_a1015-6; author reply 1017-9 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aAnticoagulants _xadministration & dosage |
| 650 | 0 | 4 |
_aEnoxaparin _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Failure, Chronic _xmetabolism |
| 650 | 0 | 4 | _aReproducibility of Results |
| 700 | 1 | _aSpencer, A P | |
| 773 | 0 |
_tPharmacotherapy _gvol. 21 _gno. 8 _gp. 1015-6; author reply 1017-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1592/phco.21.11.1015.34515 _zAvailable from publisher's website |
| 999 |
_c11632978 _d11632978 |
||